Conditions: Plaque-type Psoriasis
Keywords: Psoriasis plaque inflammatory skin disease scaly patches AIN457 secukinumab Moderate to severe
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 43
Healthy volunteers: no

Brief summary:
The study will assess the safety and efficacy of intravenous (10mg/kg) and subcutaneous (300mg) secukinumab in moderate to severe chronic plaque-type psoriasis who are partial responders to secukinumab.

Detailed description:

Arms:
arm 1: During the intravenous (I.V.) period, participants received two 150 mg s.c. injections of AIN457 at randomization and week 4, and AIN457 placebo I.V. at randomization, week 2 and week 4. During the maintenance period, participants received 300 mg s.c. of open-label AIN457. arm 2: During the I.V. period, participants received AIN457 10mg/kg I.V. at randomization, week 2 and week 4, and AIN457 placebo s.c. at randomization and week 4. During the maintenance period, participants received 300 mg s.c. of open-label AIN457.

Interventions: intervention 1: secukinumab 150mg intervention 2: secukinumab 10mg/kg i.v. regimen
Intervention descriptions: intervention 1: secukinumab 150mg (2 injections per dose) intervention 2: secukinumab 10mg/kg i.v. regimen

Protocol document: